Advertisement

Clinical and Experimental Nephrology

, Volume 20, Issue 5, pp 699–702 | Cite as

X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene

  • Xue Jun Fu
  • Kandai NozuEmail author
  • Aya Eguchi
  • Yoshimi Nozu
  • Naoya Morisada
  • Akemi Shono
  • Mariko Taniguchi-Ikeda
  • Yuko Shima
  • Koichi Nakanishi
  • Igor Vorechovsky
  • Kazumoto Iijima
Original Article

Abstract

Background

X-linked Alport syndrome (XLAS) is a progressive hereditary nephropathy caused by mutations in the type IV collagen alpha chain 5 gene (COL4A5). Although many COL4A5 mutations have previously been identified, pathogenic synonymous mutations have not yet been described.

Methods

A family with XLAS underwent mutational analyses of COL4A5 by PCR and direct sequencing, as well as transcript analysis of potential splice site mutations. In silico analysis was also conducted to predict the disruption of splicing factor binding sites. Immunohistochemistry (IHC) of kidney biopsies was used to detect α2 and α5 chain expression.

Results

We identified a hemizygous point mutation, c.876A>T, in exon 15 of COL4A5 in the proband and his brother, which is predicted to result in a synonymous amino acid change, p.(Gly292Gly). Transcript analysis showed that this mutation potentially altered splicing because it disrupted the splicing factor binding site. The kidney biopsy of the proband showed lamellation of the glomerular basement membrane (GBM), while IHC revealed negative α5(IV) staining in the GBM and Bowman’s capsule, which is typical of XLAS.

Conclusions

This is the first report of a synonymous COL4A5 substitution being responsible for XLAS. Our findings suggest that transcript analysis should be conducted for the future correct assessment of silent mutations.

Keywords

Synonymous mutation COL4A5 Splicing Silent mutation 

Notes

Acknowledgments

This study was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Subject ID: 15K09691 to Kandai Nozu) and a Health Labour Sciences Research Grant for Research on Measures for Intractable Diseases (H26-nanchitou-ippan-036 to Kazumoto Iijima).

Compliance with ethical standards

Conflict of interest

Kandai Nozu has received lecture fees from Novartis Pharma K.K. and Taisho Pharm. Co. Kazumoto Iijima has received grants from Pfizer Japan, Inc., Daiichi Sankyo Co., Ltd., Japan Blood Product Organization, Miyarisan Pharmaceutical Co., Ltd., AbbVie LLC, CSL Behring, JCR Pharmaceuticals Co., Ltd., and Teijin Pharma Ltd.; lecture fees from MSD, ALEXION Pharmaceuticals, AstraZeneca K.K., Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., Zenyaku Kogyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo, Co., Ltd., Springer Japan, and Asahi Kasei Pharma Corp; and consulting fees from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., and Takeda Pharmaceutical Company Ltd.

Supplementary material

10157_2015_1197_MOESM1_ESM.docx (3.9 mb)
Supplementary material 1 (DOCX 4023 kb)

References

  1. 1.
    Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol. 1998;9(9):1736–50.PubMedGoogle Scholar
  2. 2.
    Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364–75.CrossRefPubMedGoogle Scholar
  3. 3.
    Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. 2000;11(4):649–57.PubMedGoogle Scholar
  4. 4.
    Nozu K, Iijima K, Ohtsuka Y, Fu XJ, Kaito H, Nakanishi K, Vorechovsky I. Alport syndrome caused by a COL4A5 deletion and exonization of an adjacent AluY. Mol Genet Genom Med. 2014;2(5):451–3.CrossRefGoogle Scholar
  5. 5.
    Nozu K, Vorechovsky I, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, Hashimoto F, Kamei K, Ito S, Kaku Y, et al. X-linked Alport syndrome caused by splicing mutations in COL4A5. Clin J Am Soc Nephrol. 2014;9(11):1958–64.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hashimura Y, Nozu K, Kaito H, Nakanishi K, Fu XJ, Ohtsubo H, Hashimoto F, Oka M, Ninchoji T, Ishimori S, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV alpha5 chain. Kidney Int. 2014;85(5):1208–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaito H, Nozu K, Fu XJ, Kamioka I, Fujita T, Kanda K, Krol RP, Suminaga R, Ishida A, Iijima K, et al. Detection of a transcript abnormality in mRNA of the SLC12A3 gene extracted from urinary sediment cells of a patient with Gitelman’s syndrome. Pediatr Res. 2007;61(4):502–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Naito I, Kawai S, Nomura S, Sado Y, Osawa G. Relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome. Japanese Alport Network. Kidney Int. 1996;50(1):304–11.CrossRefPubMedGoogle Scholar
  9. 9.
    Nakanishi K, Iijima K, Kuroda N, Inoue Y, Sado Y, Nakamura H, Yoshikawa N. Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome. J Am Soc Nephrol. 1998;9(8):1433–40.PubMedGoogle Scholar
  10. 10.
    Sado Y, Kagawa M, Kishiro Y, Sugihara K, Naito I, Seyer JM, Sugimoto M, Oohashi T, Ninomiya Y. Establishment by the rat lymph node method of epitope-defined monoclonal antibodies recognizing the six different alpha chains of human type IV collagen. Histochem Cell Biol. 1995;104(4):267–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3(4):285–98.CrossRefPubMedGoogle Scholar
  12. 12.
    Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2010;21(5):876–83.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transpl. 2002;17(7):1218–27.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2015

Authors and Affiliations

  • Xue Jun Fu
    • 1
  • Kandai Nozu
    • 1
    Email author
  • Aya Eguchi
    • 2
  • Yoshimi Nozu
    • 1
  • Naoya Morisada
    • 1
  • Akemi Shono
    • 1
  • Mariko Taniguchi-Ikeda
    • 1
  • Yuko Shima
    • 3
  • Koichi Nakanishi
    • 3
  • Igor Vorechovsky
    • 4
  • Kazumoto Iijima
    • 1
  1. 1.Department of PediatricsKobe University Graduate School of MedicineKobeJapan
  2. 2.Department of NephrologySaiseikai Kawaguchi General HospitalSaitamaJapan
  3. 3.Department of PediatricsWakayama Medical UniversityWakayamaJapan
  4. 4.Faculty of MedicineUniversity of SouthamptonSouthamptonUK

Personalised recommendations